Redpin Therapeutics

Redpin Therapeutics

Pharmaceuticals, 101 6th Ave Fl 3, New York, 10013, United States, 1-10 Employees

redpinrx.com

  • LinkedIn

phone no Phone Number: 19*********

Who is REDPIN THERAPEUTICS

Redpin Therapeutics is a privately-held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies ...

Read More

map
  • 101 6th Ave Fl 3, New York, New York, 10013, United States Headquarters: 101 6th Ave Fl 3, New York, New York, 10013, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 80 | NAICS Code: 62 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from REDPIN THERAPEUTICS

Redpin Therapeutics Org Chart and Mapping

Employees

Nita Shah

Clinical Quality Assurance & Regulatory Affairs Head

Nita Patel

Head of Clinical Quality Assurance

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Redpin Therapeutics

Answer: Redpin Therapeutics's headquarters are located at 101 6th Ave Fl 3, New York, 10013, United States

Answer: Redpin Therapeutics's phone number is 19*********

Answer: Redpin Therapeutics's official website is https://redpinrx.com

Answer: Redpin Therapeutics's revenue is $1 Million to $5 Million

Answer: Redpin Therapeutics's SIC: 80

Answer: Redpin Therapeutics's NAICS: 62

Answer: Redpin Therapeutics has 1-10 employees

Answer: Redpin Therapeutics is in Pharmaceuticals

Answer: Redpin Therapeutics contact info: Phone number: 19********* Website: https://redpinrx.com

Answer: Redpin Therapeutics is a privately-held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy. Our science is based on the groundbreaking discovery and development of an ultrapotent ion channel-based chemogenetics platform that enables targeted cell activation or inhibition controlled by low doses of the anti-smoking drug varenicline (CHANTIX).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access